Our findings not only shed light on the mechanistic aspects of this process but also have clinical implications, highlighting the critical role of the PRMT6–TRAF6–EZH2 axis in the aggressiveness of glioblastoma. This evidence concerns the gene TRAF6 and glioblastoma.